首页> 外文期刊>The Journal of Nuclear Medicine >Metabotropic Glutamate Subtype 5 Receptors Are Quantified in the Human Brain with a Novel Radioligand for PET.
【24h】

Metabotropic Glutamate Subtype 5 Receptors Are Quantified in the Human Brain with a Novel Radioligand for PET.

机译:代谢型谷氨酸亚型5受体在人脑中用PET的新型放射性配体定量。

获取原文
获取原文并翻译 | 示例
           

摘要

We developed a radioligand, 3-fluoro-5-(2-(2-(18)F-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile ((18)F-SP203), for metabotropic glutamate subtype 5 (mGluR5) receptors that showed both promising (high specific binding) and problematic (defluorination) imaging characteristics in animals. The purposes of this initial evaluation in human subjects were to determine whether (18)F-SP203 is defluorinated in vivo (as measured by uptake of radioactivity in the skull) and to determine whether the uptake in the brain can be quantified as distribution volume relative to concentrations of (18)F-SP203 in plasma. METHODS: Seven healthy subjects were injected with (18)F-SP203 (323 +/- 87 MBq) and scanned over 5 h, with rest periods outside the camera. The concentrations of (18)F-SP203, separated from radiometabolites, were measured in arterial plasma. RESULTS: The skull was difficult to visualize on PET images in the initial 2 h, because of high radioactivity in the brain. Although radioactivity in the skull and adjacent cortex showed some cross-contamination, the concentration of radioactivity in the skull was less than half of that in the adjacent cortex during the initial 2 h. Modeling of regional brain and plasma data showed that a 2-tissue-compartment model was superior to a 1-tissue-compartment model, consistent with measurable amounts of both receptor-specific and nonspecific binding. The concentrations of activity in the brain measured with PET were consistently greater than the modeled values at late but not early time points and may well have been caused by the slow accumulation of radiometabolites in the brain. To determine an adequate time for more accurate measurement of distribution volume, we selected a scan duration (i.e., 2 h) associated with maximal or near-maximal identifiability. Distribution volume was well identified ( approximately 2%) by only 2 h (and even just 1) of image acquisition. CONCLUSION: This initial evaluation of (18)F-SP203 in healthy human subjects showed that defluorination is relatively small and that brain uptake can be robustly calculated as distribution volume. The values of distribution volume were well identified and had relatively small variation in this group of 7 subjects. These results suggest that (18)F-SP203 will have good sensitivity to measure mGluR5 receptors for both within-subject studies (e.g., receptor occupancy) and between-subject studies (e.g., patients vs. healthy subjects).
机译:我们为代谢型谷氨酸亚型5(mGluR5)开发了放射性配体3-氟-5-(2-(2-(2-(18)F-(氟甲基)噻唑-4-基)乙炔基)苄腈((18)F-SP203) )在动物中表现出有希望的(高特异性结合)和有问题的(脱氟)成像特征的受体。在人类受试者中进行此初始评估的目的是确定(18)F-SP203是否在体内脱氟(通过在颅骨中吸收放射性来衡量),并确定在大脑中的摄取是否可以量化为相对于分布体积至血浆中的(18)F-SP203浓度。方法:向七名健康受试者注射(18)F-SP203(323 +/- 87 MBq),并在5小时内进行扫描,休息时间在相机外。在动脉血浆中测量了与放射性代谢产物分离的(18)F-SP203的浓度。结果:由于脑部高放射性,头2小时内很难在PET图像上看到头骨。尽管颅骨和邻近皮质的放射性显示出一些交叉污染,但在最初的2小时内,颅骨中放射性的浓度小于邻近皮质的放射性浓度的一半。区域脑和血浆数据的建模显示2组织隔室模型优于1组织隔室模型,这与可测量的受体特异性和非特异性结合量一致。用PET测量的大脑中的活性浓度在后期但并非早期都始终高于模型值,这很可能是由于放射性代谢产物在大脑中的缓慢积累引起的。为了确定足够的时间来更准确地测量分布量,我们选择了与最大或接近最大可识别性相关的扫描持续时间(即2小时)。仅通过2个小时(甚至只有1个小时)的图像采集就可以很好地识别出分布量(大约2%)。结论:在健康人受试者中对(18)F-SP203的初步评估表明,脱氟作用相对较小,并且脑吸收量可以可靠地计算为分布量。在这7名受试者中,分布体积的值得到了很好的识别,并且变化相对较小。这些结果表明,(18)F-SP203对于受试者内研究(例如,受体占有率)和受试者间研究(例如,患者与健康受试者)均具有良好的灵敏度来测量mGluR5受体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号